Everything you need to know about TrumpRx

Also: Vertex's CRISPR treatment for sickle cell disease hits an unexpected roadblock ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

February 5, 2026 Check out STAT+

Sponsored By

Andrew Harnik/Getty Images What to know about TrumpRx, the Trump administration's prescription drug platform Will TrumpRx accept insurance? Is TrumpRx open to all? Answers to frequently asked questions as White House unveils new portal that partners with GoodRx. By Elaine Chen, John Wilkerson, and Chelsea Cirruzzo STAT+ | Vertex's CRISPR treatment for sickle cell disease hits unexpected roadblock Vertex's Casgevy can essentially cure sickle cell patients, but problems collecting stem cells are slowing uptake and threatening its edge. By Jason Mast STAT+ | Novo Nordisk accuses Hims & Hers of 'illegal mass compounding' over a cheaper version of Wegovy pill Hims & Hers called Novo Nordisk's angry reaction to its announcement "as predictable as it is outdated and false." By Ed Silverman Kayla Bartkowski/Getty Images STAT+ | Inside HHS' anti-fraud efforts: An aggressive crackdown sweeps up mainly Democratic-led states The approach by CMS Administrator Mehmet Oz and others is a break from the traditional federal focus on individual providers suspected of wrongdoing. By Chelsea Cirruzzo STAT+ | A rival goes after Ocular Therapeutix on eve of pivotal readout on eye treatment The CEO of Eyepoint Pharmaceuticals is said to have trash-talked Ocular's drug at a recent investor conference. By Adam Feuerstein STAT+ | Nektar Therapeutics is trying to stage a comeback. But a big test awaits Upcoming results from a mid-stage trial of rezepg, a treatment for eczema, or atopic dermatitis, could be pivotal for the drugmaker. By Adam Feuerstein Alex Hogan/STAT A sneak peek of pharma's Super Bowl ads: GLP-1s, tight ends, and more FDA announced a crackdown on TV pharmaceutical advertising last fall. This week's STATus Report looks at which Super Bowl ads may be pushing the limits. By Alex Hogan

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser